Compare ALNT & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALNT | TYRA |
|---|---|---|
| Founded | 1962 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 1995 | 2021 |
| Metric | ALNT | TYRA |
|---|---|---|
| Price | $90.93 | $25.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $64.50 | $47.50 |
| AVG Volume (30 Days) | 199.2K | ★ 889.3K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.16% | N/A |
| EPS Growth | ★ 67.09 | N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | ★ $554,478,000.00 | N/A |
| Revenue This Year | $7.53 | N/A |
| Revenue Next Year | $6.64 | N/A |
| P/E Ratio | $106.09 | ★ N/A |
| Revenue Growth | ★ 4.62 | N/A |
| 52 Week Low | $41.75 | $12.10 |
| 52 Week High | $118.67 | $40.65 |
| Indicator | ALNT | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 43.98 | 47.43 |
| Support Level | $87.76 | $24.58 |
| Resistance Level | $90.93 | $27.02 |
| Average True Range (ATR) | 4.26 | 1.91 |
| MACD | -0.22 | -0.05 |
| Stochastic Oscillator | 30.17 | 58.81 |
Allient Inc, formerly Allied Motion Technologies Inc designs, manufactures, and sells precision and specialty controlled motion components and systems. The firm mainly caters to the Industrial, Vehicle, Aerospace & Defense, and Medical sectors. It mainly operates and sells across the United States, Canada, South America, Europe, and Asia. Its products and solutions include nano precision positioning systems, servo control systems, motion controllers, digital servo amplifiers and drives, brushless servo, torque, and coreless motors, brush motors, integrated motor drives, gear motors, gearing, incremental and absolute optical encoders, active (electronic) and passive (magnetic) filters for power quality and harmonic issues.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.